Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson’s Disease

(2014) Susan H. Fox et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

(2011) Daniela Berg et al.   MOVEMENT DISORDERS

Functional models of Parkinson's disease: A valuable tool in the development of novel therapies

(2010) Peter Jenner   ANNALS OF NEUROLOGY

Formation of parkin aggregates and enhanced PINK1 accumulation during the pathogenesis of Parkinson’s disease

(2010) Ji Won Um et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brain

(2010) Salma Bukhatwa et al.   BRAIN RESEARCH

Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection

(2010) Alexander Harkavyi et al.   BRITISH JOURNAL OF PHARMACOLOGY

Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease

(2010) PJ Austin et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders

(2010) Arash Velayati et al.   Current Neurology and Neuroscience Reports

Impaired dopaminergic neuron development and locomotor function in zebrafish with loss ofpink1function

(2010) Yanwei Xi et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

An in vivo pharmacological evaluation of pardoprunox (SLV308) — A novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease

(2010) C.A. Jones et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets

(2010) K. Tayarani-Binazir et al.   EXPERIMENTAL NEUROLOGY

Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D2/D3 receptor blockade

(2010) Riccardo Viaro et al.   EXPERIMENTAL NEUROLOGY

Parkinson's disease: insights from pathways

(2010) M. R. Cookson et al.   HUMAN MOLECULAR GENETICS

In Vivo Characterization of a Dual Adenosine A2A/A1Receptor Antagonist in Animal Models of Parkinson’s Disease

(2010) Brian C. Shook et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and Its Analogues as Highly Potent Dopamine D2/D3 Agonists and as Iron Chelator: In Vivo Activity Indicates Potential Application in Symptomatic and Neuroprotective Therapy for Parkinson’s Disease

(2010) Balaram Ghosh et al.   JOURNAL OF MEDICINAL CHEMISTRY

The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra

(2010) Joanna Iczkiewicz et al.   JOURNAL OF NEUROCHEMISTRY

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

(2010) William J Marks et al.   LANCET NEUROLOGY

Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets

(2010) Louisa Clare Johnston et al.   MOVEMENT DISORDERS

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

(2010) Daniella Rylander et al.   NEUROBIOLOGY OF DISEASE

Involvement of Nitric Oxide in Maneb- and Paraquat-Induced Parkinson’s Disease Phenotype in Mouse: Is There Any Link with Lipid Peroxidation?

(2010) Satya Prakash Gupta et al.   NEUROCHEMICAL RESEARCH

Genetic Analysis of Pathways to Parkinson Disease

(2010) John Hardy   NEURON

Genetic Animal Models of Parkinson's Disease

(2010) Ted M. Dawson et al.   NEURON

Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice

(2010) Francisco Pan-Montojo et al.   PLoS One

Drug-induced Valvulopathy: An Update

(2010) Chandikumar S. Elangbam   TOXICOLOGIC PATHOLOGY

Lessons from the rotenone model of Parkinson's disease

(2010) J. Timothy Greenamyre et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Parkinson's Disease and Residential Exposure to Maneb and Paraquat From Agricultural Applications in the Central Valley of California

(2009) S. Costello et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration

(2009) Konstantinos Pothakos et al.   BMC NEUROSCIENCE

Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio)

(2009) L. Flinn et al.   BRAIN

Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model

(2009) E. Decamp et al.   BRAIN RESEARCH

Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction

(2009) K.A. Stockwell et al.   EXPERIMENTAL NEUROLOGY

Sleep disorders in Parkinson's disease: The contribution of the MPTP non-human primate model

(2009) Quentin Barraud et al.   EXPERIMENTAL NEUROLOGY

Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease

(2009) G.E. Meredith et al.   EXPERIMENTAL NEUROLOGY

MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease

(2009) D. Galter et al.   GENES BRAIN AND BEHAVIOR

The dopamine D2 receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with l-dopa

(2009) Michael John Jackson et al.   JOURNAL OF NEURAL TRANSMISSION

Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α-synuclein inclusions

(2009) Claire Gibrat et al.   JOURNAL OF NEUROCHEMISTRY

Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice

(2009) Tohru Kitada et al.   JOURNAL OF NEUROCHEMISTRY

Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila

(2009) C.-H. Ng et al.   JOURNAL OF NEUROSCIENCE

LRRK2 Modulates Vulnerability to Mitochondrial Dysfunction in Caenorhabditis elegans

(2009) S. Saha et al.   JOURNAL OF NEUROSCIENCE

Metabotropic Glutamate 7 Receptor Subtype Modulates Motor Symptoms in Rodent Models of Parkinson's Disease

(2009) B. Greco et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism

(2009) Glenda Halliday et al.   MOVEMENT DISORDERS

A highly reproducible rotenone model of Parkinson's disease

(2009) Jason R. Cannon et al.   NEUROBIOLOGY OF DISEASE

Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology

(2009) Robert E. Drolet et al.   NEUROBIOLOGY OF DISEASE

Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention

(2009) Malú G. Tansey et al.   NEUROBIOLOGY OF DISEASE

Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice

(2009) Masatoshi Inden et al.   NEUROCHEMISTRY INTERNATIONAL

Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synuclein

(2009) Xian Lin et al.   NEURON

Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinsonʼs model

(2009) Anthony C. Vernon et al.   NEUROREPORT

Molecular basis of Parkinsonʼs disease

(2009) Yan Xiang Yang et al.   NEUROREPORT

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

(2009) E. Sidransky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys

(2009) Laurent Grégoire et al.   PARKINSONISM & RELATED DISORDERS

From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease

(2009) Peter Jenner   PARKINSONISM & RELATED DISORDERS

The MitoPark Mouse – An animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons

(2009) Mats I. Ekstrand et al.   PARKINSONISM & RELATED DISORDERS

Role of dopamine receptor agonists in the treatment of early Parkinson's disease

(2009) Ubaldo Bonuccelli et al.   PARKINSONISM & RELATED DISORDERS

Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease

(2009) Dirk W. Luchtman et al.   PHYSIOLOGY & BEHAVIOR

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

(2009) Y. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dopamine Gene Therapy for Parkinson's Disease in a Nonhuman Primate Without Associated Dyskinesia

(2009) B. Jarraya et al.   Science Translational Medicine

Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?

(2009) Francesca Cicchetti et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Patients With Advanced Parkinson Disease and Motor Fluctuations

(2008) Olivier Rascol   ARCHIVES OF NEUROLOGY

Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines

(2008) Bernard R. Neustadt et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo

(2008) Tianhong Pan et al.   BRAIN RESEARCH

Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat

(2008) Shane Grealish et al.   BRAIN RESEARCH BULLETIN

Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease

(2008) Andrew J. Lees   CNS Neuroscience & Therapeutics

Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets

(2008) K.A. Stockwell et al.   EXPERIMENTAL NEUROLOGY

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson’s disease

(2008) Naomi P. Visanji et al.   FASEB JOURNAL

Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements

(2008) Werner J. Schmidt et al.   JOURNAL OF NEURAL TRANSMISSION

Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid

(2008) Daniel Alvarez-Fischer et al.   JOURNAL OF NEUROCHEMISTRY

Depletion of 26S Proteasomes in Mouse Brain Neurons Causes Neurodegeneration and Lewy-Like Inclusions Resembling Human Pale Bodies

(2008) L. Bedford et al.   JOURNAL OF NEUROSCIENCE

Selective Activation of p38 Mitogen-Activated Protein Kinase in Dopaminergic Neurons of Substantia Nigra Leads to Nuclear Translocation of p53 in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Mice

(2008) S. Karunakaran et al.   JOURNAL OF NEUROSCIENCE

 1-Adrenoceptors Mediate Dihydroxyphenylalanine-Induced Activity in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaques

(2008) N. P. Visanji et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Decreased NURR1 gene expression in patients with Parkinson's disease

(2008) Weidong Le et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Non-dopaminergic treatments in development for Parkinson's disease

(2008) Susan H Fox et al.   LANCET NEUROLOGY

Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4

(2008) C. M. Niswender et al.   MOLECULAR PHARMACOLOGY

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS

Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease

(2008) Jose A. Obeso et al.   MOVEMENT DISORDERS

PITX3 polymorphism is associated with early onset Parkinson's disease

(2008) Olle Bergman et al.   NEUROBIOLOGY OF AGING

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD

(2008) R. Katzenschlager et al.   NEUROLOGY

Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocol

(2008) Gloria E. Meredith et al.   PARKINSONISM & RELATED DISORDERS

A Drosophila model for LRRK2-linked parkinsonism

(2008) Z. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inflammation as a causative factor in the aetiology of Parkinson's disease

(2007) P S Whitton   BRITISH JOURNAL OF PHARMACOLOGY

Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish

(2007) Lu Wen et al.   DEVELOPMENTAL BIOLOGY

In vivo alpha-synuclein overexpression in rodents: A useful model of Parkinson's disease?

(2007) Marie-Francoise Chesselet   EXPERIMENTAL NEUROLOGY

Cell systems and the toxic mechanism(s) of α-synuclein

(2007) Mark R. Cookson et al.   EXPERIMENTAL NEUROLOGY

Glial reactions in Parkinson's disease

(2007) Patrick L. McGeer et al.   MOVEMENT DISORDERS

The transcription factor PITX3 is associated with sporadic Parkinson's disease

(2007) Julia Fuchs et al.   NEUROBIOLOGY OF AGING